ADO and non-small cell lung carcinoma: These results suggest that the immunologically inert phenotype (low PD-L1 expression, low TMB, and low CD8+ T cells) of mEGFR NSCLC may be attributed to the upregulation of the NT5E (encoding the exonucleosidase CD73) and ADO A1 receptor genes in the ADO pathway.